• Dansk
  • NL
  • EN
  • FI
  • FR
  • DE
  • EL
  • IT
  • NO
  • PL
  • PT
  • RO
  • SL
  • ES
  • SV

Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health

A new report released today reveals the dramatic extent of the pharmaceutical industry's lobbying efforts towards EU decision-makers, with the industry spending an estimated 15 times more than civil society actors working on public health or access to medicines.

'Policy prescriptions: the firepower of the EU pharmaceutical lobby and implications for public health' by Corporate Europe Observatory probes the privileged access to decision-making in Brussels enjoyed by the sector and facilitated by a lobby spend of around €40 million, extensive meetings with policy-makers, and presence in advisory groups. Under-reporting and the continued avoidance by some of the EU's voluntary lobby transparency system mean that overall industry spending may be much higher than the transparency register reveals.

The report shows that Big Pharma enjoys a staggering number of meetings with European Commission departments and officials. For example, influential EU pharmaceutical trade association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), had over 50 meetings with the Juncker Commission in its first four and a half months of office.

The study examines some of Big Pharma’s channels of influence in the EU and exposes concrete examples of EU law and policies that have been targeted or shaped by the industry. These include rules around clinical trials’ data transparency, trade secrets, and the negotiation of the EU-US trade deal, the Transatlantic Trade and Investment Partnership (TTIP).

It also puts pharma lobby group EFPIA in the spotlight, examining its goals, tactics, access and influence, including a critique of the EU’s multi-billion euro public-private partnership with EFPIA, the ‘Innovative Medicines Initiative’.

Report: http://corporateeurope.org/sites/default/files/20150904_bigpharma_web.pdf

 

Help!

Exposing the lobbying of big business costs money. Would you consider a donation to help us continue? We refuse funding from the EU, governments, political parties and corporations to be as independent as possible, so every single donation really helps. Thanks!

 

 

 

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Stop ISDS campaign 2019

Since 2010, ExxonMobil has invested over €35 million in lobbying the European Union to delay and weaken essential climate action. With a climate catastrophe looming, is it time EU decision-makers closed the door on the corporation's dirty lobbying?

In an open letter to European Commissioner Bieńkowska we've expressed the grave concerns of several civil society groups and political parties involved in running major European cities about flaws in the European Commission’s preparation of the Services Notification Procedure Directive, which put local democracy at risk.

Two years after the suspension of the Transatlantic Trade and Investment Partnership (TTIP), EU member states and the European Commission are preparing mandates for new trade negotiations with the US. Once again corporate lobby groups are working to set the agenda for the talks, while the Commission covers over its links with big business.

New information shows the chilling scope of proposed EU rules on services (the ‘Bolkestein Directive’) that would give the Commission advance veto power over decisions taken by parliaments and city councils on a vast range of services, including everything from childcare, to energy, to water, and even sex work.

Get our monthly newsletter

Follow us on social media

Lobby Planet 2017 banner